News

AB-Therapeutics new anticancer compounds reduce by 70% lung tumors growth

The Barcelona based biotech company is in a series-A fundraising round to conduct preclinical development and to file an IND in late 2011

November 8, 2010

The Barcelona-based biotech company AB Therapeutics has obtained high efficacy results with its 2 new anticancer compounds in animal models of lung cancer (NSCLC) using Membrane Lipid Therapy (MLT), a new therapeutic approach. After 4 weeks treatment in immunosupressed mice, the molecules reduced tumor growth in treated animals by 70%. Additionally, tumor growth arrest was observed in 10% of treated mice. Adverse events were markedly lower than in mice treated with gold standard treatment docetaxel.
AB-Therapeutics is in a series-A fundraising round to conduct preclinical development and to file an IND in 3Q2011 to start phase I clinical trials in late 2011. Capital needs are 0.8-1 M€ in 2010, 2.8 M€ in 2011 and 5 M€ in 2012. The company expects to receive 2 M€ in government soft loans from European, Spanish and Catalan institutions.
 
“We are satisfied to have in vivo validation of in vitro results, not only in efficacy but also in low toxicity”, said Jordi Espadaler, PhD, VP Discovery Research. “The results obtained will allow us to build the regulatory preclinical package to start clinical trials next year. We have initiated a series A round of financing to accomplish this goal”, said Carles Domenech, PhD, CEO.
 
Dr. Domenech highlights that MLT “could represent an important contribution to human health”, and also points at its high market potential: “Our compounds have blockbuster potential due to the high mortality in lung cancer, still an unmet medical need”.
 
ABOUT MEMBRANE LIPID THERAPY
MLT is a new therapeutic approach, with a mechanism of action consisting in modifying the dynamics of cell membranes, thus altering the activity of multiple proteins involved in cell growth regulation.
 
Molecules under preclinical development selectively induce apoptosis in several cancer types: lung, pancreatic, glioma and leukemia.
 
ABOUT AB-THERAPEUTICS
 
AB-Therapeutics, SL is a drug discovery and development company headquartered in Barcelona, Catalonia, Spain, with planned US facilities in Boston. The company was cofounded in late 2009 by AB Biotics, SA, a company publicly traded at the Spanish alternative stock market (MAB), Carles Domenech (CEO) and Jordi Espadaler (VP Discovery Research).
 
AB-Therapeutics, SL develops safer human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. It has a molecule ready to start preclinical development in 4Q2010, with Phase I clinical trials (first in man) starting in late 2011 / early 2012. A second drug candidate will start preclinical development in 2Q2011.
 
 
Contact:
Media relations:
Nuria Peláez
Tel. +34 902 903 844
media.relations@ab-therapeutics.com
 
Investors:
Carles Domènech, PhD
Tel. +34 935 868 977
contact@ab-therapeutics.com

LATEST NEWS

05.12.2018

News

AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018

News

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
19.02.2018

News

AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
13.12.2017

News

AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + info
05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG